Kraematon Investment Advisors’s Ocular Therapeutix OCUL Stock Holding History

Kraematon Investment Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$827K	Buy	+97,617	New	+$930K	0.67%	46

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Kraematon Investment Advisors's OCUL Position: Q1 2026 in Review

Kraematon Investment Advisors opened a new position in Ocular Therapeutix (OCUL) in Q1 2026: 97,617 shares worth $827K. The stake represents 0.67% of the portfolio and ranks #46 among its holdings.

269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

Kraematon Investment Advisors held 97,617 shares of Ocular Therapeutix worth $827K as of Q1 2026.
Ocular Therapeutix was a new Kraematon Investment Advisors position in Q1 2026.
Ocular Therapeutix made up 0.67% of Kraematon Investment Advisors's portfolio in Q1 2026, its #46 holding.
269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Kraematon Investment Advisors's 13F filing for Q1 2026, filed 13 May 2026.